The effect of interferon β-1a on optic neuritis relapse in patients with multiple sclerosis

  • Yan-Ming Chen
  • Chih-Chao Yang
  • I-Hua Wang
  • Fung-Rong Hu
  • Jieh-Ren Jou



To evaluate the clinical effect of interferon β-1a on optic neuritis (ON) relapse in patients with multiple sclerosis (MS) in Taiwan.


Data were collected from 23 MS patients with ON at National Taiwan University Hospital between January 1, 1993 and February 1, 2007. Twenty-three MS patients with ON received interferon β-1a (Rebif) 44 µg via subcutaneous injection three times weekly. All patients received corticosteroids pulse therapy followed by oral prednisolone for acute ON. The annual relapse rate (ARR) of ON in these MS patients before and after the use of interferon β-1a (Rebif) was the main clinical parameter of outcome in this study.


The ARR of ON was lower in the posttreatment period than in the pretreatment period (P = 0.0068). Thirteen patients (56.5%) had improved final visual acuity (>2 lines), and the other ten patients (43.5%) had stable final visual outcome (−2 lines < X < 2 lines). In addition, no recurrence of ON was noted in 15 patients (65.2%) during the posttreatment period.


The use of interferon β-1a 44 µg via subcutaneous injection three times weekly did not increase the ON attacks in MS patients receiving this treatment. In addition, beneficial effects were found with the use of interferon β-1a on these patients.


Optic neuritis Multiple sclerosis Interferon β-1a Immune-modulation agents 


  1. 1.
    Söderström M, Jin YP, Hillert J, Link H (1998) Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 50:708–714PubMedGoogle Scholar
  2. 2.
    Ikuta F, Zimmerman HM (1976) Distribution of plaques in seventy autopsy cases of multiple sclerosis in the United States. Neurology 26:26–28PubMedGoogle Scholar
  3. 3.
    Toussaint D, Perier O, Verstappen A, Bervoets S (1983) Clinicopathological study of the visual pathways, eyes, and cerebral hemispheres in 32 cases of disseminated sclerosis. J Clin Neuroophthalmol 3:211–220PubMedGoogle Scholar
  4. 4.
    Sandberg-Wollheim M, Bynke H, Cronqvist S, Holtås S, Platz P, Ryder LP (1990) A long-term prospective study of optic neuritis: evaluation of risk factors. Ann Neurol 27:386–393CrossRefPubMedGoogle Scholar
  5. 5.
    Rodriquez M, Siva A, Cross SA, O'Brien PC, Kurland LT (1995) Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology 45:244–250Google Scholar
  6. 6.
    O’Riordan JI, Thompson AJ, Kingsley DP, MacManus DG, Kendall BE, Rudge P, McDonald WI, Miller DH (1998) The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 121:495–503CrossRefPubMedGoogle Scholar
  7. 7.
    Kira JI (2003) Multiple sclerosis in the Japanese population. Lancet Neurol 2:117–127CrossRefPubMedGoogle Scholar
  8. 8.
    Hung TP, Landsborough D, Hsi MS (1976) Multiple sclerosis amongst Chinese in Taiwan. J Neurol Sci 27:459–484CrossRefPubMedGoogle Scholar
  9. 9.
    Tsai CP, Yuan CL, Yu HY, Chen C, Guo YC, Shan DE (2004) Multiple sclerosis in Taiwan. J Chin Med Assoc 67:500–505PubMedGoogle Scholar
  10. 10.
    Lin YC, Yen MY, Hsu WM, Lee HC, Wang AG (2006) Low conversion rate to multiple sclerosis in idiopathic optic neuritis patients in Taiwan. Jpn J Ophthalmol 50:170–175CrossRefPubMedGoogle Scholar
  11. 11.
    Woung LC, Lin CH, Tsai CY, Tsai MT, Jou JR, Chou P (2007) Optic neuritis among national health insurance enrollees in Taiwan, 2000–2004. Neuroepidemiology 29:250–254CrossRefPubMedGoogle Scholar
  12. 12.
    Rudick RA (2001) Contemporary immunomodulatory therapy for multiple sclerosis. J Neuroophthalmol 21:284–291PubMedGoogle Scholar
  13. 13.
    European Study Group on Interferon Beta-1b in Secondary Progressive MS (1998) Placebo-controlled multicenter randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352:1491–1497CrossRefGoogle Scholar
  14. 14.
    PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498–1504CrossRefGoogle Scholar
  15. 15.
    Beck RW, Chandler DL, Cole SR, Simon JH, Jacobs LD, Kinkel RP, Selhorst JB, Rose JW, Cooper JA, Rice G, Murray TJ, Sandrock AW (2002) Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 51:481–490CrossRefPubMedGoogle Scholar
  16. 16.
    CHAMPS Study Group (2001) Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol 132:463–471CrossRefGoogle Scholar
  17. 17.
    Wang AG, Lin YC, Wang SJ, Tsai CP, Yen MY (2006) Early relapse in multiple sclerosis-associated optic neuritis following the use of interferon b-1a in chinese patients. Jpn J Ophthalmol 50:537–542CrossRefPubMedGoogle Scholar
  18. 18.
    McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127CrossRefPubMedGoogle Scholar
  19. 19.
    Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485–1489CrossRefPubMedGoogle Scholar
  20. 20.
    Beck RW, Cleary PA (1993) Optic Neuritis Treatment Trial: one-year follow-up results. Arch Ophthalmol 111:773–775PubMedGoogle Scholar
  21. 21.
    Perkin GD, Rose FC (1979) Optic neuritis and its differential diagnosis. Oxford Medical Publications, EnglandGoogle Scholar
  22. 22.
    Optic Neuritis Study Group (2008) Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology 115:1079–1082CrossRefGoogle Scholar
  23. 23.
    Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR, Savino PJ, Guy JR, Trobe JD, McCrary JA III, Smith CH, Chrousos GA, Thompson HS, Katz BJ, Brodsky MC, Goodwin JA, Atwell CW (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 326:581–588PubMedCrossRefGoogle Scholar
  24. 24.
    Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J (1999) A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 52(7):1479–1484PubMedGoogle Scholar
  25. 25.
    Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW, Brown CH (1993) The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 329:1764–1769CrossRefPubMedGoogle Scholar
  26. 26.
    Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343:898–904CrossRefPubMedGoogle Scholar
  27. 27.
    Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, Hartung H, Seeldrayers P, Sørensen PS, Rovaris M, Martinelli V, Hommes OR (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 357:1576–1582CrossRefPubMedGoogle Scholar
  28. 28.
    Arnold AC (2005) Evolving Management of Optic Neuritis and Multiple Sclerosis. Am J Ophthalmol 139:1101–1108CrossRefPubMedGoogle Scholar
  29. 29.
    Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, Pohl C, Sandbrink R (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67:1242–1249CrossRefPubMedGoogle Scholar
  30. 30.
    Saida T, Tashiro K, Itoyama Y, Sato T, Ohashi Y, Zhao Z (2005) Interferon beta-1b Multiple Sclerosis Study Group of Japan. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Neurology 64:621–630PubMedGoogle Scholar
  31. 31.
    Mikol DD (2001) Treat early, but treat hard: Interferon-beta dose makes a difference. J Neuroophthalmol 21:237–239PubMedGoogle Scholar
  32. 32.
    Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53:1107–1114PubMedGoogle Scholar
  33. 33.
    Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106–2112CrossRefPubMedGoogle Scholar
  34. 34.
    Papeix C, Vidal JS, de Seze J, Pierrot-Deseilligny C, Tourbah A, Stankoff B, Lebrun C, Moreau T, Vermersch P, Fontaine B, Lyon-Caen O, Gout O (2007) Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 13:256–259CrossRefPubMedGoogle Scholar
  35. 35.
    Warabi Y, Matsumoto Y, Hayashi H (2007) Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 252:57–61CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Yan-Ming Chen
    • 1
    • 2
  • Chih-Chao Yang
    • 3
  • I-Hua Wang
    • 4
  • Fung-Rong Hu
    • 1
  • Jieh-Ren Jou
    • 1
  1. 1.Department of OphthalmologyNational Taiwan University HospitalTaipeiTaiwan
  2. 2.Department of Ophthalmology, E-Da HospitalI-Shou UniversityKaohsiungTaiwan
  3. 3.Department of NeurologyNational Taiwan University HospitalTaipeiTaiwan
  4. 4.Department of OphthalmologyCathay General HospitalTaipeiTaiwan

Personalised recommendations